ARMP: Armata Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Armata Pharmaceuticals (ARMP)

Market fluctuations in Armata Pharmaceuticals (ARMP) shares on the GURU.Markets platform reflect debt dynamics, which currently stand at 0.00. The business relies on developing anti-infectives using automated component synthesis, while physicians remain responsible for the final testing stage and patient supervision. The company's stability is guaranteed by the humanitarian status of its developments in the US, which minimizes external risks.

ARMP (Armata Pharmaceuticals Inc) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

ARMP (Armata): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Armata Pharmaceuticals, Inc.|ARMP - Fair Value Consensus
- market capitalization information:
Market Value Armata Pharmaceuticals, Inc.|ARMP - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Armata Pharmaceuticals|ARMP - Book Capitalization|Market Cap to Net Assets Ratio armatapharma.com|ARMP - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Armata Pharmaceuticals|ARMP - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Armata Pharmaceuticals|ARMP - Company Total Debt Obligations|Debts to Book Capitalization Armata Pharmaceuticals, Inc.|ARMP - Company Long-Term Liabilities|Company Short-Term Debt Armata Pharmaceuticals|Quick Liquidity armatapharma.com
- net income and valuation multiples indicators:
ARMP - Company Net Income
Fundamental company analysis:Armata Pharmaceuticals, Inc. (ARMP)
Mass-produced product of Armata

This metric measures the total volume of liabilities with a maturity of up to one year. It allows for an assessment of liquidity risk and the extent of the issuer's dependence on external refinancing. By analyzing the dynamics of the current debt load, an investor identifies critical points of potential cash flow gaps. For Armata Pharmaceuticals (ARMP), this determines the funding stability of the R&D platform. Debt control is critical as biopharmaceutical molecules transition to mid-stage clinical trials.

Competitor analysis

ACXP - Company Short-Term Debt